I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Sep 17 / Roche and Genentech

Educational video on BCVA & visual function

Description

This video discusses visual function assessments for patients with geography atrophy, describing the limitations of best-corrected visual acuity.

Sign up or login to unlock the full suite of MEDICALLY features

Related Content

Sign up or login to unlock the full suite of MEDICALLY features

Feb 28 / Roche and Genentech
Interleukin-6 Receptor Signalling Inhibition With Satralizumab▼ in Thyroid Eye Disease: Phase 3 SatraGO-1 and SatraGO-2 Trial Design
We describe the design of the SatraGO-1 and SatraGO-2 trials, which are identical, global, phase 3, randomised, double-masked, placebo-controlled, 72-week multicentre studies investigating IL-6 receptor inhibition via satralizumab▼ in thyroid eye disease.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 21 / Roche and Genentech
Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema
This presentation describes an analysis investigating the relationship between the reduction in intraretinal fluid volume after 3 months of treatment and 2-year anatomic and visual outcomes in patients with diabetic macular edema. This post hoc analysis is based on treatment agnostic data from the phase 3 YOSEMITE and RHINE trials.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 18 / Roche and Genentech
Retinal Fluid and Thickness Fluctuations in Pagoda Trial of PDS in Patients With DME
This presentation describes results from a post hoc analysis investigating retinal fluid and thickness fluctuations and the impact of these features on vision outcomes in patients with DME in the phase 3 Pagoda trial. In patients with DME, continuous delivery with PDS controlled retinal fluctuations and maintained vision over 48 weeks, comparable to IVT.